At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Lerapolturev +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lerapolturev (Formerly Known as PVSRIPO) With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
In Brief
A Phase 2 clinical trial evaluating Lerapolturev and Anti-PD-1 Checkpoint Inhibitor for Melanoma. Completed, enrolled 27 participants across 12 sites.
Detailed Summary
A Phase 2 study to investigate the efficacy and safety of lerapolturev alone or in combination with a programmed death receptor-1 (anti-PD-1) inhibitor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionNov 2024
TodayJul 2026
First PostedOct 8, 2020
Enrollment StartNov 17, 2020
Primary CompletionNov 15, 2024
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 5.7 years ago
Interventions
Lerapolturevbiological
Lerapolturev administered via direct lesion injection
Anti-PD-1 Checkpoint Inhibitorbiological
Anti-PD-1 Checkpoint Inhibitor administered per package insert instructions